Faculty Profiles - MORISE Masahiro

Papers - MORISE Masahiro

Division display 61 - 80 of about 93 ／ All the affair displays >>

Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study Reviewed International journal

Shimokawa, M; Nosaki, K; Seto, T; Ohashi, K; Morise, M; Horinouchi, H; Sakakibara, J; Murakami, H; Yano, S; Satouchi, M; Matsumoto, S; Goto, K; Yoh, K

TRIALS Vol. 21 ( 1 ) page： 298 2020.3

Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study Reviewed International journal

Okada Norio, Iwama Shintaro, Okuji Takayuki, Kobayashi Tomoko, Yasuda Yoshinori, Wada Eri, Onoue Takeshi, Goto Motomitsu, Sugiyama Mariko, Tsunekawa Taku, Takagi Hiroshi, Hagiwara Daisuke, Ito Yoshihiro, Suga Hidetaka, Banno Ryoichi, Hase Tetsunari, Morise Masahiro, Kanda Mitsuro, Yokota Kenji, Hashimoto Naozumi, Ando Masahiko, Fujimoto Yasushi, Nagino Masato, Kodera Yasuhiro, Fujishiro Mitsuhiro, Hibi Hideharu, Sone Michihiko, Kiyoi Hitoshi, Gotoh Momokazu, Ando Yuichi, Akiyama Masashi, Hasegawa Yoshinori, Arima Hiroshi

BRITISH JOURNAL OF CANCER Vol. 122 ( 6 ) page： 771 - 777 2020.3

Risk factors for pulmonary infection after diagnostic bronchoscopy in patients with lung cancer Reviewed International journal

Shimizu, T; Okachi, S; Imai, N; Hase, T; Morise, M; Hashimoto, N; Sato, M; Hasegawa, Y

NAGOYA JOURNAL OF MEDICAL SCIENCE Vol. 82 ( 1 ) page： 69 - 77 2020.2

Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer Reviewed International journal

Nakagawa, K; Hida, T; Nokihara, H; Morise, M; Azuma, K; Kim, YH; Seto, T; Takiguchi, Y; Nishio, M; Yoshioka, H; Kumagai, T; Hotta, K; Watanabe, S; Goto, K; Satouchi, M; Kozuki, T; Koyama, R; Mitsudomi, T; Yamamoto, N; Asakawa, T; Hayashi, M; Hasegawa, W; Tamura, T

LUNG CANCER Vol. 139 page： 195 - 199 2020.1

Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study Reviewed International journal

Kobayashi, T; Iwama, S; Yasuda, Y; Okada, N; Okuji, T; Ito, M; Onoue, T; Goto, M; Sugiyama, M; Tsunekawa, T; Takagi, H; Hagiwara, D; Ito, Y; Suga, H; Banno, R; Yokota, K; Hase, T; Morise, M; Hashimoto, N; Ando, M; Fujimoto, Y; Hibi, H; Sone, M; Ando, Y; Akiyama, M; Hasegawa, Y; Arima, H

JOURNAL FOR IMMUNOTHERAPY OF CANCER Vol. 8 ( 2 ) 2020

Multicenter, placebo-controlled, double-blind, randomized study of fosnetupitant in combination with palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy Reviewed International journal

Sugawara, S; Inui, N; Kanehara, M; Morise, M; Yoshimori, K; Kumagai, T; Fukui, T; Minato, K; Iwashima, A; Takeda, Y; Kubota, K; Saeki, T; Tamura, T

CANCER Vol. 125 ( 22 ) page： 4076 - 4083 2019.11

Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non-Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors Reviewed International journal

Fukihara, J; Sakamoto, K; Koyama, J; Ito, T; Iwano, S; Morise, M; Ogawa, M; Kondoh, Y; Kimura, T; Hashimoto, N; Hasegawa, Y

CLINICAL LUNG CANCER Vol. 20 ( 6 ) page： 442 - + 2019.11

The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV. Reviewed International journal

Akamatsu H, Ninomiya K, Kenmotsu H, Morise M, Daga H, Goto Y, Kozuki T, Miura S, Sasaki T, Tamiya A, Teraoka S, Tsubata Y, Yoshioka H, Hattori Y, Imamura CK, Katsuya Y, Matsui R, Minegishi Y, Mizugaki H, Nosaki K, Okuma Y, Sakamoto S, Sone T, Tanaka K, Umemura S, Yamanaka T, Amano S, Hasegawa K, Morita S, Nakajima K, Maemondo M, Seto T, Yamamoto N

International journal of clinical oncology Vol. 24 ( 7 ) page： 731 - 770 2019.7

Potential for afatinib as an optimal treatment for advanced non-small cell lung carcinoma in patients with uncommon EGFR mutations Reviewed International journal

Tanaka Ichidai, Morise Masahiro, Kodama Yuta, Matsui Akira, Ozawa Naoya, Ozone Sachiko, Goto Daiki, Miyazawa Ayako, Hase Tetsunari, Hashimoto Naozumi, Sato Mitsuo, Hasegawa Yoshinori

LUNG CANCER Vol. 127 page： 169 - 171 2019.1

eIF2 beta, a subunit of translation-initiation factor EIF2, is a potential therapeutic target for non-small cell lung cancer Reviewed International coauthorship International journal

Tanaka Ichidai, Sato Mitsuo, Kato Toshio, Goto Daiki, Kakumu Tomohiko, Miyazawa Ayako, Yogo Naoyuki, Hase Tetsunari, Morise Masahiro, Sekido Yoshitaka, Girard Luc, Minna John D., Byers Lauren A., Heymach John V., Coombes Kevin R., Kondo Masashi, Hasegawa Yoshinori

CANCER SCIENCE Vol. 109 ( 6 ) page： 1843 - 1852 2018.6

Safety and efficacy of diagnostic flexible bronchoscopy in very old patients with lung cancer Reviewed International journal

Okachi Shotaro, Imaizumi Kazuyoshi, Imai Naoyuki, Shimizu Takahiro, Hase Tetsunari, Morise Masahiro, Hashimoto Naozumi, Sato Mitsuo, Hasegawa Yoshinori

EUROPEAN GERIATRIC MEDICINE Vol. 9 ( 2 ) page： 255 - 262 2018.4

Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study Reviewed International journal

Kobayashi Tomoko, Iwama Shintaro, Yasuda Yoshinori, Okada Norio, Tsunekawa Taku, Onoue Takeshi, Takagi Hiroshi, Hagiwara Daisuke, Ito Yoshihiro, Morishita Yoshiaki, Goto Motomitsu, Suga Hidetaka, Banno Ryoichi, Yokota Kenji, Hase Tetsunari, Morise Masahiro, Hashimoto Naozumi, Ando Masahiko, Kiyoi Hitoshi, Gotoh Momokazu, Ando Yuichi, Akiyama Masashi, Hasegawa Yoshinori, Arima Hiroshi

JOURNAL OF THE ENDOCRINE SOCIETY Vol. 2 ( 3 ) page： 241 - 251 2018.3

Prospective registry database of patients with malignant mesothelioma: directions for a future Japanese registry-based lung cancer study Reviewed International journal

Shintani Yasushi, Hasegawa Seiki, Takuwa Teruhisa, Aoe Keisuke, Kato Katsuya, Fujimoto Nobukazu, Hida Yasuhiro, Morise Masahiro, Moriya Yasumitsu, Morohoshi Takao, Okumura Meinoshin, Yoshino Ichiro

JOURNAL OF THORACIC DISEASE Vol. 10 ( 3 ) page： 1968 - 1971 2018.3

A phase II trial of Ifosfamide combination with recommended supportive therapy for recurrent SCLC in second-line and heavily treated setting Reviewed International journal

Tanaka, I; Kawada, K; Morise, M; Hase, T; Hayashi, H; Sokai, A; Fukatsu, A; Kondo, M; Nomura, F; Hasegawa, Y

CANCER CHEMOTHERAPY AND PHARMACOLOGY Vol. 81 ( 2 ) page： 339 - 345 2018.2

An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib Reviewed International journal

Sato Mitsuo, Matsui Akira, Shimoyama Yoshie, Omote Norihito, Morise Masahiro, Hase Tetsunari, Tanaka Ichidai, Suzuki Kojiro, Hasegawa Yoshinori

Internal Medicine Vol. 57 ( 23 ) page： 3429 - 3432 2018

Language：English Publishing type：Research paper (scientific journal) Publisher：The Japanese Society of Internal Medicine

Squamous cell carcinoma (SCC) transformation has been identified as a mechanism of resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), gefitinib or erlotinib, in EGFR-mutated lung cancer. However, whether second- or third-generation TKIs can overcome resistance due to SCC transformation remains unclear. We herein report an EGFR-mutated lung adenocarcinoma undergoing transformation into SCC that exhibited a durable response to afatinib, which is a second-generation irreversible EGFR-TKI. We suggest that afatinib can be considered as a treatment option for EGFR-mutated tumor undergoing SCC transformation, particularly in the absence of a T790M mutation.

DOI： 10.2169/internalmedicine.0999-18

Web of Science

PubMed

CiNii Research

Risk Factor Evaluation of Programmed Death 1 Inhibitor Related Pneumonitis in Patients with Non-Small Cell Lung Cancer Reviewed International journal

Fukihara, J; Sakamoto, K; Iwano, S; Morise, M; Hashimoto, N; Hasegawa, Y

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE Vol. 197 2018

12. Clinical Practice of Lung Cancer in Elderly Patients International journal

Hasegawa Yoshinori, Morise Masahiro

Nihon Naika Gakkai Zasshi Vol. 106 ( 9 ) page： 1986 - 1990 2017.9

Identification of proteasomal catalytic subunit PSMA6 as a therapeutic target for lung cancer Reviewed International coauthorship International journal

Kakumu Tomohiko, Sato Mitsuo, Goto Daiki, Kato Toshio, Yogo Naoyuki, Hase Tetsunari, Morise Masahiro, Fukui Takayuki, Yokoi Kohei, Sekido Yoshitaka, Girard Luc, Minna John D., Byers Lauren A., Heymach John V., Coombes Kevin R., Kondo Masashi, Hasegawa Yoshinori

CANCER SCIENCE Vol. 108 ( 4 ) page： 732 - 743 2017.4

Impact of mild to moderate COPD on feasibility and prognosis in non-small cell lung cancer patients who received chemotherapy Reviewed International journal

Omote, N; Hashimoto, N; Morise, M; Sakamoto, K; Miyazaki, S; Ando, A; Nakahara, Y; Hasegawa, Y

INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE Vol. 12 page： 3541 - 3547 2017

Can we predict the development of serious adverse events (SAEs) and early treatment termination in elderly non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy? Reviewed International journal

Kato, T; Morise, M; Ando, M; Kojima, E; Ogasawara, T; Suzuki, R; Shindoh, J; Matsumoto, M; Sugino, Y; Ogawa, M; Nozaki, Y; Hase, T; Kondo, M; Saito, H; Hasegawa, Y

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY Vol. 142 ( 7 ) page： 1629 - 1640 2016.7

　 PREV - NEXT 　

<MORISE Masahiro>

Papers - MORISE Masahiro